Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program
dc.contributor.author | Azar, Rabih R. | |
dc.contributor.author | Ragy, Hany | |
dc.contributor.author | Kozan, Omer | |
dc.contributor.author | El Khuri, Maurice | |
dc.contributor.author | Bazergani, Nooshin | |
dc.contributor.author | Marler, Sabrina | |
dc.contributor.author | Teutsch, Christine | |
dc.contributor.author | Ibrahim, Mohammed | |
dc.contributor.author | Lip, Gregory Y. H. | |
dc.contributor.author | Huisman, Menno | |
dc.contributor.pubmedID | 33912651 | en_US |
dc.contributor.researcherID | ABC-9349-2021 | en_US |
dc.date.accessioned | 2022-08-31T12:00:43Z | |
dc.date.available | 2022-08-31T12:00:43Z | |
dc.date.issued | 2021 | |
dc.description.abstract | Background: Data on the epidemiology and treatment of atrial fibrillation in the Africa/Middle East region are limited, and the use of novel oral anticoagulants and their effectiveness in real-world clinical practice has not been evaluated. Methods and Results: This study used prospectively collected data from the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation (GLORIA-AF) to describe anticoagulant use and outcomes in Africa and the Middle East. Baseline characteristics of patients newly diagnosed with nonvalvular atrial fibrillation from Lebanon (242 patients, 40.3%), Saudi Arabia (236 patients, 39.3%), United Arab Emirates (87 patients, 14.5%), and South Africa (35 patients, 5.8%) were described, and clinical outcomes were investigated for all patients in this region who received dabigatran. In newly diagnosed patients (having a diagnosis within the last three months) with nonvalvular atrial fibrillation in Africa and the Middle East, the observed uptake of non-vitamin K oral anticoagulants was high in the first years following their availability; dabigatran was the most commonly used antithrombotic agent (314/600 patients), and only 1.5% of patients did not receive any antithrombotic therapy. Use of dabigatran was associated with a high persistence rate (>88% at 24 months) and low incidence rates of stroke, myocardial infarction, major bleeding, and all-cause mortality after 2 years of follow-up. Conclusions: Data from GLORIA-AF reveal a change in the landscape for stroke prevention in the AME region, and the results were consistent with those observed in the global GLORIA-AF registry, as well as those of randomized clinical trials. (C) 2021 The Authors. Published by Elsevier B.V. | en_US |
dc.identifier.eissn | 2352-9067 | en_US |
dc.identifier.scopus | 2-s2.0-85103954002 | en_US |
dc.identifier.uri | https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2352906721000518?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2352906721000518%3Fshowall%3Dtrue&referrer=https:%2F%2Fwww.webofscience.com%2F | |
dc.identifier.uri | http://hdl.handle.net/11727/7476 | |
dc.identifier.volume | 34 | en_US |
dc.identifier.wos | 000667480400021 | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1016/j.ijcha.2021.100763 | en_US |
dc.relation.journal | IJC HEART & VASCULATURE | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Anticoagulant | en_US |
dc.subject | Atrial fibrillation | en_US |
dc.subject | NOACs | en_US |
dc.title | Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program | en_US |
dc.type | article | en_US |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- 1-s2.0-S2352906721000518.pdf
- Size:
- 318.59 KB
- Format:
- Adobe Portable Document Format
- Description:
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: